ESMO Voices from China | Professor Wenbin Li: Breaking Through the Blood–Brain Barrier — Novel Targeted Therapy and Chemotherapy Regimens Offer New Hope for Survival in Recurrent Glioma

ESMO Voices from China | Professor Wenbin Li: Breaking Through the Blood–Brain Barrier — Novel Targeted Therapy and Chemotherapy Regimens Offer New Hope for Survival in Recurrent Glioma

Recurrent high-grade glioma (HGG) is associated with an extremely poor prognosis, particularly in patients with IDH-wildtype disease, whose median overall survival (OS) is only 6–10 months. Although targeted therapies have made progress, treatment of central nervous system (CNS) tumors remains extremely challenging because of the physiological barrier posed by the blood–brain barrier (BBB). At the 2026 European Society for Medical Oncology (ESMO) Congress, the team led by Professor Wenbin Li, Head of the Department of Neuro-Oncology at Beijing GoBroad Hospital, presented two research findings: an oral presentation of phase I data on the novel BRAF inhibitor HSK42360 in recurrent glioma, and large-scale prospective multicenter data on teniposide combined with platinum-based chemotherapy for recurrent HGG. On October 31, the 6th iHope Innovation Medicine Forum was held, focusing on the development of an Academic Research Organization (ARO) clinical research system and showcasing GoBroad Hospital's capabilities in building international multicenter clinical research networks and translating cutting-edge technologies into clinical practice. In this article, Professor Wenbin Li discusses breakthroughs in the clinical translation of innovative drugs and the evolving landscape of neuro-oncology treatment from the perspectives of translational medicine and clinical research.
ESMO 2026 | Professor Jiwei Huang: Exploring Personalized Treatment for Non-Clear Cell Renal Cell Carcinoma Through Targeted Therapy Plus Immunotherapy—The Clinical Rationale, Efficacy Signals, and Identification of Benefiting Patient Populations in the FRONTIER Study

ESMO 2026 | Professor Jiwei Huang: Exploring Personalized Treatment for Non-Clear Cell Renal Cell Carcinoma Through Targeted Therapy Plus Immunotherapy—The Clinical Rationale, Efficacy Signals, and Identification of Benefiting Patient Populations in the FRONTIER Study

During the 2026 European Society for Medical Oncology (ESMO) Congress, updated results from the FRONTIER study exploring first-line fruquintinib plus serplulimab in non-clear cell renal cell carcinoma were presented. Non-clear cell renal cell carcinoma encompasses multiple pathological subtypes with substantial differences in biological behavior and molecular characteristics, and the available treatment evidence remains limited. Oncology Frontier – UroStream invited Professor Jiwei Huang from Renji Hospital, Shanghai Jiao Tong University School of Medicine, to discuss the rationale behind the study design, updated efficacy data, and biomarker investigations, providing insights into research directions for personalized treatment of non-clear cell renal cell carcinoma.
Professor Jun Guo: Addressing Unmet Clinical Needs to Explore a New Treatment Approach for Favorable-Risk Renal Cell Carcinoma — Balancing Tumor Control with Long-Term Tolerability: The Rationale Behind Ivonescimab

Professor Jun Guo: Addressing Unmet Clinical Needs to Explore a New Treatment Approach for Favorable-Risk Renal Cell Carcinoma — Balancing Tumor Control with Long-Term Tolerability: The Rationale Behind Ivonescimab

During the 2026 European Society for Medical Oncology (ESMO) Congress, first-line treatment options for patients with favorable-risk advanced renal cell carcinoma (RCC) attracted considerable attention. For this patient population, how to control disease while reducing the burden of long-term treatment remains an important question warranting further investigation. Oncology Frontier – UroStream invited Professor Jun Guo of Peking University Cancer Hospital to discuss the patient selection, dual-target blockade strategy, and potential clinical value of ivonescimab.
Professor Zhenhua Liu: Exploring the Potential of PSMA-Targeted ADCs in Advanced Prostate Cancer — From Early SHR-4394 Findings and Patient Selection to Combination Therapy Strategies

Professor Zhenhua Liu: Exploring the Potential of PSMA-Targeted ADCs in Advanced Prostate Cancer — From Early SHR-4394 Findings and Patient Selection to Combination Therapy Strategies

Patients with advanced prostate cancer whose disease continues to progress despite multiple lines of treatment urgently need new therapeutic options. At the 2026 European Society for Medical Oncology (ESMO) Congress, the Phase I study of SHR-4394, an antibody–drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), attracted considerable attention. Oncology Frontier – UroStream invited Professor Zhenhua Liu of West China Hospital, Sichuan University, to discuss the clinical needs addressed by this study, patient selection, safety and preliminary antitumor activity, as well as future directions in drug design and combination therapy.
ESMO 2026 | Oligometastatic Cervical Cancer Study Reports Promising Results: QL1706 Plus Chemotherapy Followed by Definitive Radiotherapy Achieves an ORR of 90.91%

ESMO 2026 | Oligometastatic Cervical Cancer Study Reports Promising Results: QL1706 Plus Chemotherapy Followed by Definitive Radiotherapy Achieves an ORR of 90.91%

Patients with oligometastatic cervical cancer face a risk of systemic recurrence but may also benefit from aggressive local treatment. During ESMO 2026, results were reported from a Chinese single-arm Phase II study evaluating QL1706 plus chemotherapy, followed by definitive radiotherapy and continued immunotherapy maintenance. A total of 28 patients were enrolled. Among the 22 evaluable patients, the objective response rate (ORR) was 90.91%, and the disease control rate (DCR) was 100%. After a median follow-up of 8.25 months, median progression-free survival (PFS) had not yet been reached. Oncology Frontier invited Professor Peng Xie from Shandong Cancer Hospital and Institute, affiliated with Shandong First Medical University, to discuss the study design, efficacy findings, and safety management, and to share his perspectives on clinical practice.
ESMO LBA Insights | Pursuing Both Survival and Function: Professor Yue He Discusses the OPTIMAL Study

ESMO LBA Insights | Pursuing Both Survival and Function: Professor Yue He Discusses the OPTIMAL Study

In the treatment of head and neck cancers, particularly oral squamous cell carcinoma (OSCC), clinicians have long faced a difficult trade-off: achieving radical tumor control often requires surgery that sacrifices critical anatomical structures, including the tongue, floor of the mouth, and jawbone, all of which are essential for speech, swallowing, and appearance. To further reduce the risk of local recurrence, postoperative radiotherapy or concurrent chemoradiotherapy is frequently added. However, the resulting complications, such as trismus, xerostomia, dysphagia, and tissue fibrosis, can continue to impair patients' quality of life for years.
ESMO LBA Insights | Professor Jong Chul Park Discusses the HexAgon-HN Study

ESMO LBA Insights | Professor Jong Chul Park Discusses the HexAgon-HN Study

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. During the Head and Neck Cancer Oral Presentation Session, the Phase II results of the HexAgon-HN study (LBA42) were presented. The study evaluated the efficacy and safety of the hexavalent OX40 agonist INBRX-106 plus pembrolizumab (P) versus pembrolizumab monotherapy as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) with a PD-L1 combined positive score (CPS) ≥20. The results showed that the objective response rate (ORR) in the combination group reached 48.3%, representing an absolute improvement of 21.8 percentage points over the monotherapy group (26.5%). The benefit was particularly pronounced in the HPV-positive subgroup (80.0% vs. 33.3%). This also represents the first positive proof-of-concept result from a randomized controlled trial of an OX40 costimulatory pathway agonist in cancer immunotherapy.